SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-007983
Filing Date
2022-05-10
Accepted
2022-05-10 08:30:32
Documents
54
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20220331x10q.htm   iXBRL 10-Q 1653834
2 EX-31.1 ruby-20220331xex31d1.htm EX-31.1 18871
3 EX-31.2 ruby-20220331xex31d2.htm EX-31.2 18791
4 EX-32.1 ruby-20220331xex32d1.htm EX-32.1 8117
5 EX-32.2 ruby-20220331xex32d2.htm EX-32.2 8098
  Complete submission text file 0001558370-22-007983.txt   4994837

Data Files

Seq Description Document Type Size
6 EX-101.SCH ruby-20220331.xsd EX-101.SCH 30220
7 EX-101.CAL ruby-20220331_cal.xml EX-101.CAL 39365
8 EX-101.DEF ruby-20220331_def.xml EX-101.DEF 115866
9 EX-101.LAB ruby-20220331_lab.xml EX-101.LAB 303406
10 EX-101.PRE ruby-20220331_pre.xml EX-101.PRE 211443
48 EXTRACTED XBRL INSTANCE DOCUMENT ruby-20220331x10q_htm.xml XML 602495
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 22907515
SIC: 2836 Biological Products, (No Diagnostic Substances)